Agency for Strategic Initiatives approved the project of a pharmaceutical company from Tomsk

The project was approved at a session of the ASI Open Expert Council attended by Russian Prime Minister Vladimir Putin held on February 17 in Krasnoyarsk as part of the Krasnoyarsk Economic Forum.

The project "Production of proprietary plant-based pharmaceuticals" was submitted by OOO Solagran Son from Tomsk. It will bring to the market a new generation of drugs to treat liver diseases. Their active ingredients will be produced using proprietary biotechnological techniques for value added processing of plant material.

Denis Molotkov, Deputy Mayor of Tomsk for Investment, took part in negotiations to solicit support of the ASI for this project.

"Our producers need assistance at the federal level to overcome administrative barriers in the process of registration of proprietary pharmaceuticals. Today it is difficult. There is a need to simplify the clinical trials procedures and facilitate the inclusion of Tomsk drugs in the recommended drugs lists issued by the Russian Ministry of Health", he said.

Denis Molotkov also explained that Solagran Son counts on the ASI's assistance in structuring the deal to take out an almost 1.5bn rubles loan to start production. The project will be started-up in 2015. The project will generate by 2019 the annual revenue of 29,614m rubles.

Background

OOO Solagran Son is a resident of the Tomsk SEZ. The company has pilot production lines in Tomsk and Vyshny Volochek (Tver Region).

The project for the construction of a new GMP certified pharmaceutical plant in the Tomsk SEZ has been developed. The start-up is scheduled for 2015. The new drugs – up to 15 articles – will come to the market the same year. The annual revenue will reach 29,614m rubles by 2019.

• 
• February
•